Now showing items 1-2 of 2

    • Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. 

      Vaughan, L; Clarke, PA; Barker, K; Chanthery, Y; Gustafson, CW; Tucker, E; Renshaw, J; Raynaud, F; Li, X; Burke, R; Jamin, Y; Robinson, SP; Pearson, A; Maira, M; Weiss, WA; Workman, P; Chesler, L (2016-09)
      MYC oncoproteins deliver a potent oncogenic stimulus in several human cancers, making them major targets for drug development, but efforts to deliver clinically practical therapeutics have not yet been realized. In childhood ...
    • Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. 

      Basu, B; Krebs, MG; Sundar, R; Wilson, RH; Spicer, J; Jones, R; Brada, M; Talbot, DC; Steele, N; Ingles Garces, AH; Brugger, W; Harrington, EA; Evans, J; Hall, E; Tovey, H; de Oliveira, FM; Carreira, S; Swales, K; Ruddle, R; Raynaud, FI; Purchase, B; Dawes, JC; Parmar, M; Turner, AJ; Tunariu, N; Banerjee, S; de Bono, JS; Banerji, U (2018-09)
      Background:We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients ...